Real-World study tests whether aggressive early treatment improves psoriatic arthritis outcomes

This study follows people newly diagnosed with psoriatic arthritis (PsA) to see how a 'treat to target' approach works in everyday clinics. Participants receive standard care, often starting with methotrexate, and their disease activity is tracked over time. The goal is to understand whether aiming for a specific low-disease target leads to better real-life results. This cohort also serves as a foundation for future embedded trials testing new therapies.